Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL8378170 | 0.96 | KMT2A (0.64) | KMT2AHTTFAAHCYP3A4CYP2D6 | |
| SCHEMBL10808716 | 0.85 | KMT2A (0.53) | KMT2AHTTMAPK1MEN1POLB | |
| SCHEMBL2948216 | 0.79 | KMT2A (0.62) | KMT2AHTTFAAHCYP3A4CYP2D6 | |
| SCHEMBL19741751 | 0.79 | — | — | |
| SCHEMBL965286 | 0.79 | KMT2A (0.82) | KMT2AHTTMAPK1RAB9APOLB | |
| SCHEMBL17273858 | 0.77 | KMT2A (0.78) | KMT2AHTTMAPK1RAB9AMEN1 | |
| SCHEMBL4803949 | 0.77 | KMT2A (0.78) | KMT2AHTTMAPK1RAB9AMEN1 | |
| SCHEMBL966438 | 0.77 | KMT2A (0.78) | KMT2AHTTMAPK1RAB9AMEN1 | |
| SCHEMBL13674468 | 0.75 | KMT2A (0.83) | KMT2AHTTFAAHCYP3A4CYP2D6 | |
| SCHEMBL962662 | 0.75 | KMT2A (0.75) | KMT2AHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763623-B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1539753-B1 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| EP-1539753-B1 | PYRAZOLO(3,4-B)PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| WO-2007087204-A2 | HETEROCYCLES AS NICOTINIC ACID RECEPTOR AGONISTS FOR THE TREATMENT OF DYYSLIPIDEMIA | SCHERING CORPOORATION (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | SCHERING CORPORATION | 2007-07-26 | — | — | US | disclosed |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173495-A1 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | GPR119, HCAR1, LDLR | KMT2A 3399/4885HTT 478/4885FAAH 953/4885 |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | KMT2A 2690/4885HTT 4837/4885FAAH 1933/4885 |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | KMT2A 2690/4885HTT 4837/4885FAAH 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.